The Hoosier state has 17,093 industry jobs spread out among 69 companies, from Indianapolis-based drugmaker Eli Lilly and Co. to startups scattered around the state, but mostly in clusters near research universities.
Telemedicine is a $21 billion worldwide industry that has long promised to overhaul health care but struggled as recently as six months ago to get steady traction.
The Greenfield-based company, which spun off from Eli Lilly and Co. in 2018, said it expects the deal to close in early August.
Much of routine health care came to a halt in March as hospitals cleared space for an expected wave of COVID-19 patients and authorities ordered a halt to surgeries and other procedures that could be postponed.
The Indianapolis drugmaker also said it expects to begin dosing patients in a complementary clinical study in the U.S. in the coming days.
The Indianapolis-based insurer says the treatments are “investigational”—or still under clinical study—but a California woman claims the electrical stimulation is FDA-approved and supported by numerous studies.
Taltz rang up sales of $1.3 billion last year, an increase of 46%, making it Lilly’s fastest-growing drug. An estimated 137,000 patients have been treated with Taltz worldwide since its launch four years ago.
Philip and Martin Low’s latest venture, Eradivir, was incorporated in February to develop a treatment that would fight the influenza virus, but COVID-19 prompted a tweak to the business plan.
Around the world, more than 80 vaccine projects are under development by pharmaceutical companies and university research laboratories.
The not-for-profit and its health research are a testament to the idea that all innovation is related—even when the connection appears tenuous at first glance.
The company is one of many across the globe in a mad rush to develop radioligand therapies for cancer treatment—a field that’s expected to see explosive growth.
The Indiana Donor Network Organ and Tissue Recovery Center has re-tasked two operating rooms and an intensive care unit to recover major organs, such as the kidneys, heart and lungs.
Washington, D.C.-area-based Maximus is taking on a critical, massive assignment: helping health departments across Indiana contact people who have tested positive for COVID-19 to learn whom they might have exposed.
The IUPUI nursing professor is co-leading a study on health behaviors and health outcomes during the pandemic.
The design of the long-anticipated project was originally set to be unveiled by the end of 2018, but has been delayed several times—most recently this spring, as the pandemic began to sweep across the United States.
Hotel Tango hand sanitizer can now be found in Navy shipbuilding yards in Wisconsin, shoe retailers around the country, shipping companies that handle packages as an integral part of their business, as well as military ships and bases around the world.
The emerging health care field seeks to develop methods for replacing or reinvigorating damaged human organs, cells and tissues.
COVID-19 is not showing much mercy to seniors, or to people with high blood pressure, diabetes and other chronic conditions.
Across Indiana, local health departments have been scrambling to keep up with the job of tracking, one patient at a time, the spread of the virus that has already claimed the lives of more than 900 Hoosiers.
Gov. Eric Holcomb lifted the ban effective Monday, with some caveats, such as making sure that hospitals keep enough personnel and personal protective equipment on hand for COVID-19 patients.
